Results 221 to 230 of about 4,502,468 (335)

Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study

open access: yesBritish Journal of Haematology, EarlyView.
Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin   +27 more
wiley   +1 more source

The prostate cancer electronic health (eHealth) literacy instrument: a tool for eHealth design and patient communication

open access: yesBJU International, EarlyView.
Objective To describe the development and validation of the Prostate Cancer Electronic Health (eHealth) Literacy Instrument (P‐CeHLI). This is in response to: (i) a lack of clear and validated eHealth literacy measurement for men with prostate cancer; (ii) the unique information processing, decision making, and digital communication experience of men ...
Stuart Robert Jackson   +6 more
wiley   +1 more source

European Code Against Cancer, 5th edition - organised cancer screening programmes. [PDF]

open access: yesMol Oncol
Toes-Zoutendijk E   +19 more
europepmc   +1 more source

Diagnosis of penile cancer with ex vivo fluorescence confocal microscopy using the Histolog® Scanner

open access: yesBJU International, EarlyView.
Objectives To evaluate the feasibility and diagnostic performance of ex vivo fluorescence confocal microscopy (FCM) using the Histolog® Scanner (SamanTree Medical SA, Lausanne, Switzerland) for the assessment of penile cancer (PeCa) specimens, and to compare FCM‐based diagnoses with standard formalin‐fixed, paraffin‐embedded (FFPE) histopathology ...
Xiaohu Zhang   +8 more
wiley   +1 more source

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis.
Rui Cheng   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy